New Zealand markets closed

NeuroMetrix, Inc. (NURO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
10.60-0.28 (-2.57%)
As of 12:14PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close10.88
Bid10.56 x 800
Ask10.61 x 1000
Day's range10.47 - 10.79
52-week range1.39 - 38.75
Avg. volume9,894,464
Market cap59.666M
Beta (5Y monthly)3.07
PE ratio (TTM)N/A
EPS (TTM)-0.30
Earnings date20 Oct 2021 - 25 Oct 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend date28 Mar 2007
1y target estN/A
  • GlobeNewswire

    NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia

    WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research. The article is available online at the journal website. The article reports an intention-to-treat analysis of a double-blind, randomized, sham-controlled trial that compared 3-months of at-home treatment with a standard (active) or low

  • GlobeNewswire

    NeuroMetrix Reports Q2 2021 Financial Results

    WOBURN, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. Highlights: Revenue of $2.2 million improved 63% from $1.4 million in Q2 2020. The Q2 2020 results were adversely affected by a pandemic-related decline in customer orders. Gross margin on revenue

  • Simply Wall St.

    Companies Like NeuroMetrix (NASDAQ:NURO) Can Afford To Invest In Growth

    Just because a business does not make any money, does not mean that the stock will go down. Indeed, NeuroMetrix...